NEW YORK (GenomeWeb) – Horizon Discovery Group announced this week a $1.2 million master services agreement with an unnamed "major global diagnostic development company and a US biopharmaceutical company" to support the development of companion diagnostics for genetically targeted oncology therapies. In the first project covered by the agreement, Horizon will generate genetically defined cell lines and related gDNA and formalin-fixed, paraffin-embedded standards. Financial terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.